Ratings Avadel Pharmaceuticals plc

Equities

AVDL

IE00BDGMC594

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
15.29 ^USD	+1.06%		-2.36%	+7.15%

Jun. 05	European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	MT
May. 22	Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension Data at Sleep 2024	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
AVADEL PHARMACEUTICALS PLC	+7.15%	1.45B	-
ELI LILLY AND COMPANY	+48.39%	765B	C+
JOHNSON & JOHNSON	-6.13%	354B	C+
MERCK & CO., INC.	+20.61%	331B	B-
ABBVIE INC.	+10.00%	299B	C+
ASTRAZENECA PLC	+18.87%	248B	B+
ROCHE HOLDING AG	-1.96%	219B	A+
NOVARTIS AG	+11.11%	216B	B-
AMGEN INC.	+5.80%	164B	C+
PFIZER, INC.	-2.50%	162B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes